1. Introduction
Invasive fungal infections are increasing, and
Candida spp. is the main cause [
1]. Yeast species other than
Candida albicans are becoming more frequent, and some of them may have variable patterns of susceptibility to antifungal agents, making it important to identify them correctly [
2]. Molecular amplification methods (polymerase chain reaction (PCR)) and proteomic analysis by Matrix-assisted Laser Desorption Ionization–Time-of-flight Mass Spectrometry (MALDI-TOF MS) techniques have emerged as alternative methods [
3,
4]. The aim of this study was to evaluate the concordance of the identification of ICUs isolates, at the species level, by culture methods based on standard morphological and biochemical criteria, MALDI-TOF MS and PCR.
2. Materials and Methods
During a two-year multicenter prospective observational study in ICU patients from two tertiary hospitals located in the Lisbon metropolitan area, 988 axillar/inguinal swabs were taken and identified at the species level to unveil the prevalence of C. auris at Portuguese ICUs. This investigation has been approved by the Institutional Ethical Board of all institutions enrolled.
All swabs’ isolates (n = 371) were plated on Sabouraud Dextrose Agar and chromogenic agar (CHROMagar
®). For
C. albicans suspected colonies, a filamentation test was made. API
® Candida or API
® 20 C AUX galleries (bioMérieux, Marcy l’Etoile, France) were used for identification according to the enzyme profile and sugar assimilation pattern. PCR assays were optimized for
C. auris and
Candida cryptic species identification [
5,
6]. MALDI-TOF MS methods analysis with Vitek–MS® (bioMérieux, Marcy l’Etoile, France) system was used for definitive identification.
The following species presumptively identified by phenotypic methods from ICU patient samples were studied: C. albicans complex (n = 183), C. parapsilosis complex (n = 115), C. glabrata complex (n = 39), C. tropicalis (n = 15), C. guilliermondii (n = 3), C. famata (n = 2), C. kefyr (n = 1), Saccharomyces cerevisae (n = 1), Rhodotorula sp. (n = 9) and Trichosporon sp. (n = 3). ATCC collection strains C. parapsilosis 22019, C. glabrata 15126, C. albicans 90028 and C. auris DSMZ 21087 were included in the study.
3. Results
Identification of the 371 isolates by MALDI-TOF MS included 355 Candida species isolates. Namely, C. albicans (n = 185), C. parapsilosis complex (n = 112) [C. parapsilosis sensu stricto (n = 109), C. orthopsilosis (n = 2), C. metapsilosis (n = 1)], C. glabrata (n = 36), C. tropicalis (n = 15), C. lusitaniae (n = 4) and C. guilliermondii (n = 3). Other yeast species included: Rhodotorula rubra (n = 9); Trichosporon inkin (n = 5); Trichosporon asahii (n = 1); and S. cerevisae (n = 1). No isolate of C. auris was retrieved within this cohort. The direct concordance between the conventional identification method and MALDI-TOF MS was 92% (341/371). Discrepancies were observed with the following species: C. parapsilosis; C. glabrata; C. tropicalis; C. guilliermondii; C. famata; and C. kefyr. In this work, MALDI-TOF MS allowed the correct identification of the yeasts C. lusitaniae, C. guilliermondii, S. cerevisae, T. inkin and T. asahii erroneously identified by conventional methods such as C. parapsilosis. There was a 100% correlation between MALDI-TOF MS and PCR assays for the identification of cryptic species of C. albicans, C. parapsilosis, C. glabrata complexes and C. auris.
4. Discussion
The accurate identification of
Candida and other yeast species is extremely important, contributing to the increase of knowledge about the epidemiology of these microorganisms in the ICU setting. As already published by other authors, a limitation of conventional methods is the inability to identify cryptic species of
C. albicans,
C. parapsilosis and
C. glabrata or new emerging species like
C. auris [
7,
8,
9].
These results allow us to conclude that conventional methodologies are still useful to reliably identify the most frequently isolated yeast species from clinical samples, but when dealing with rare, uncommon, or cryptic Candida species, it is important to confirm them using technologies such as MALDI-TOF MS. The PCR assays used allowed a reliable species identification and has the potential to be implemented in a cost-effective manner into epidemiological studies to broaden the limited knowledge of cryptic and rare species.
Author Contributions
Conceptualization, T.N. and H.B.; methodology, T.N., H.B., D.G., I.F., P.D., C.T. and P.P.; investigation, T.N., H.B., D.G., I.F. and C.T.; writing—original draft preparation, T.N.; writing—review and editing, T.N., H.B. and J.I.; supervision, H.B. and J.I.; project administration, H.B.; funding acquisition, H.B. All authors have read and agreed to the published version of the manuscript.
Funding
This research was funded by Egas Moniz Cooperativa de Ensino Superior, CRL, grant number EI 19/01.
Institutional Review Board Statement
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Ethical Committee of the Prof. Doutor Fernando Fonseca Hospital on 13/11/2019 (54/2019) and by the Ethical Committee of the Beatriz Ângelo Hospital on 21/07/2021 (3655/2021).
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
MDPI Research Data Policies.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Sharma, M.; Chakrabarti, A. Candidiasis and Other Emerging Yeasts. Curr. Fungal Infect. Rep. 2023, 17, 15–24. [Google Scholar] [CrossRef] [PubMed]
- Koehler, P.; Stecher, M.; Cornely, O.A.; Koehler, D.; Vehreschild, M.J.G.T.; Bohlius, J.; Wisplinghoff, H.; Vehreschild, J.J. Morbidity and mortality of candidaemia in Europe: An epidemiologic meta-analysis. Clin. Microbiol. Infect. 2019, 25, 1200–1212. [Google Scholar] [CrossRef] [PubMed]
- Keighley, C.; Garnham, K.; Harch, S.A.J.; Robertson, M.; Chaw, K.; Teng, J.C.; Chen, S.C. Diagnostic Challenges and Emerging Opportunities for the Clinical Microbiology Laboratory. Curr. Fungal Infect. Rep. 2021, 15, 116–126. [Google Scholar] [CrossRef] [PubMed]
- Maldonado, I.; Cataldi, S.; Garbasz, C.; Relloso, S.; Striebeck, P.; Guelfand, L.; Moral, L.L.; Romeo, A.M.; Schijman, M.; Ponce, G.; et al. Identification of Candida yeasts: Conventional methods and MALDI-TOF MS. Rev. Iberoam. Micol. 2018, 35, 151–154. [Google Scholar] [CrossRef] [PubMed]
- Arastehfar, A.; Fang, W.; Pan, W.; Liao, W.; Yan, L.; Boekhout, T. Identification of nine cryptic species of Candida albicans, C. glabrata, and C. parapsilosis complexes using one-step multiplex PCR. BMC Infect. Dis. 2018, 18, 480. [Google Scholar] [CrossRef] [PubMed]
- Kordalewska, M.; Zhao, Y.; Lockhart, S.R.; Chowdhary, A.; Berrio, I.; Perlin, D.S. Rapid and Accurate Molecular Identification of the Emerging Multidrug-Resistant Pathogen Candida auris. J. Clin. Microbiol. 2017, 55, 2445–2452. [Google Scholar] [CrossRef] [PubMed]
- Zhao, Y.; Tsang, C.C.; Xiao, M.; Chan, J.F.W.; Lau, S.K.P.; Kong, F.; Xu, Y.; Woo, P.C.Y. Yeast identification by sequencing, biochemical kits, MALDI-TOF MS and rep-PCR DNA fingerprinting. Med. Mycol. 2018, 56, 816–827. [Google Scholar] [CrossRef] [PubMed]
- Lockhart, S.R.; Lyman, M.M.; Sexton, D.J. Tools for Detecting a “Superbug”: Updates on Candida auris Testing. J. Clin. Microbiol. 2022, 60, e0080821. [Google Scholar] [CrossRef]
- Rosenvinge, F.S.; Dzajic, E.; Knudsen, E.; Malig, S.; Andersen, L.B.; Løvig, A.; Arendrup, M.C.; Jensen, T.G.; Gahrn-Hansen, B.; Kemp, M. Performance of matrix-assisted laser desorption-time of flight mass spectrometry for identification of clinical yeast isolates. Mycoses 2013, 56, 229–235. [Google Scholar] [CrossRef]
| Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).